Capital Research Global Investors Denali Therapeutics Inc. Transaction History
Capital Research Global Investors
- $463 Billion
- Q3 2024
A detailed history of Capital Research Global Investors transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 7,909,114 shares of DNLI stock, worth $170 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
7,909,114
Previous 7,126,533
10.98%
Holding current value
$170 Million
Previous $165 Million
39.23%
% of portfolio
0.05%
Previous 0.04%
Shares
9 transactions
Others Institutions Holding DNLI
# of Institutions
227Shares Held
119MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$287 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$283 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$240 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$231 Million0.06% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U05.36MShares$115 Million0.64% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.88B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...